| Glutamatergic synaptic input to glioma cells drives brain tumour progression V Venkataramani, DI Tanev, C Strahle, A Studier-Fischer, L Fankhauser, ... Nature 573 (7775), 532-538, 2019 | 726 | 2019 |
| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 422 | 2018 |
| Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study P Kickingereder, F Isensee, I Tursunova, J Petersen, U Neuberger, ... The Lancet Oncology 20 (5), 728-740, 2019 | 354 | 2019 |
| Glioblastoma hijacks neuronal mechanisms for brain invasion V Venkataramani, Y Yang, MC Schubert, E Reyhan, SK Tetzlaff, ... Cell 185 (16), 2899-2917. e31, 2022 | 194 | 2022 |
| Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data G Thomalla, F Boutitie, H Ma, M Koga, P Ringleb, LH Schwamm, O Wu, ... The Lancet 396 (10262), 1574-1584, 2020 | 138 | 2020 |
| Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas M Friedrich, R Sankowski, L Bunse, M Kilian, E Green, ... Nature cancer 2 (7), 723-740, 2021 | 132 | 2021 |
| N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated … W Wick, S Dettmer, A Berberich, T Kessler, I Karapanagiotou-Schenkel, ... Neuro-oncology 21 (1), 95-105, 2019 | 122 | 2019 |
| Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma E Jung, M Osswald, M Ratliff, H Dogan, R Xie, S Weil, DC Hoffmann, ... Nature communications 12 (1), 1014, 2021 | 95 | 2021 |
| Autonomous rhythmic activity in glioma networks drives brain tumour growth D Hausmann, DC Hoffmann, V Venkataramani, E Jung, S Horschitz, ... Nature 613 (7942), 179-186, 2023 | 72 | 2023 |
| Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study CJ Preetha, H Meredig, G Brugnara, MA Mahmutoglu, M Foltyn, F Isensee, ... The Lancet Digital Health 3 (12), e784-e794, 2021 | 68 | 2021 |
| Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma T Kessler, F Sahm, J Blaes, M Osswald, P Rübmann, D Milford, S Urban, ... Oncotarget 6 (31), 31050, 2015 | 62 | 2015 |
| Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation T Kessler, F Sahm, A Sadik, D Stichel, A Hertenstein, G Reifenberger, ... Neuro-oncology 20 (3), 367-379, 2018 | 60 | 2018 |
| Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma A Wick, T Kessler, M Platten, C Meisner, M Bamberg, U Herrlinger, ... Neuro-oncology 22 (8), 1162-1172, 2020 | 54 | 2020 |
| Targeting resistance against the MDM2 inhibitor RG7388 in glioblastoma cells by the MEK inhibitor trametinib A Berberich, T Kessler, CM Thomé, S Pusch, T Hielscher, F Sahm, ... Clinical Cancer Research 25 (1), 253-265, 2019 | 53 | 2019 |
| Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions D Stichel, D Schrimpf, B Casalini, J Meyer, AK Wefers, P Sievers, ... Acta neuropathologica 138, 827-835, 2019 | 52 | 2019 |
| Cerebrospinal fluid proteomic profiling in nusinersen‐treated patients with spinal muscular atrophy T Kessler, P Latzer, D Schmid, U Warnken, A Saffari, A Ziegler, J Kollmer, ... Journal of neurochemistry 153 (5), 650-661, 2020 | 49 | 2020 |
| Glioblastoma in elderly patients: solid conclusions built on shifting sand? A Wick, T Kessler, AEH Elia, F Winkler, TT Batchelor, M Platten, W Wick Neuro-oncology 20 (2), 174-183, 2018 | 49 | 2018 |
| Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study E Pfaff, T Kessler, GP Balasubramanian, A Berberich, D Schrimpf, A Wick, ... Neuro-oncology 20 (6), 826-837, 2018 | 39 | 2018 |
| Tumor cell network integration in glioma represents a stemness feature R Xie, T Kessler, J Grosch, L Hai, V Venkataramani, L Huang, ... Neuro-oncology 23 (5), 757-769, 2021 | 34 | 2021 |
| Oligosarcomas, IDH-mutant are distinct and aggressive AK Suwala, M Felix, D Friedel, D Stichel, D Schrimpf, F Hinz, E Hewer, ... Acta neuropathologica 143 (2), 263-281, 2022 | 28 | 2022 |
